FRI0220 OCULAR SURFACE INFLAMMATORY MARKERS CORRELATED WITH IMMUNOLOGICAL PARAMETERS IN PRIMARY SJöGREN’S SYNDROME

Background: In Sjogren’s Syndrome (SS), ocular damage is mediated by inflammation induced by antibodies, enzymes, and other effectors that could be used as clinical indicators of the ocular surface damage. There is evidence suggesting that increased activity of matrix metalloproteinases (MMPs) is corelated with an increased ocular damage because of its potential inflamatory activity and could be used as a potential therapeutic target for dry eye 1,2 . Very few studies have addressed the rol betwen the ocular MMPS and the clinical parameters of SS. Objectives: To determine the level of correlation between the serological profile of autoantibodies with ophthalmological parameters at the cornea level. Methods: Cross-sectional, observational, and descriptive study. Sixty patients with a diagnosis of primary Sjogren’s syndrome (pSS) classified according to the ACR/EULAR 2016 criteria were included. The following measurements were made: Schirmer test, lacrimal osmolarity, ocular staining score (OSS), and ocular surface disease index (OSDI) and metalloproteinase-9 (MMP-9) in tear and antibodies were measured in peripheral blood serum: RF isotypes (IgA, IgG, IgM), anti-SSA/Ro and anti-SSB/La in. Results: Fifty-eight women participated (96.7%) with an average age of 53 years (± 13.01) (Table 1). We found a positive correlation between OSS and RF-IgM (rho=0.385 P=0.002), RF-IgA (rho=0.256 P=0.049), and anti-Ro/SSA (rho=0.302 P Conclusion: A significant correlation was observed between serology, ocular surface damage (OSS), and ocular surface inflammation (MMP-9). The positivity of RF isotypes IgM and IgA could alert the clinician about the ocular damage to initiate a study directed to this organ. Nevertheless this present study shows preeliminary outcomes, we need to enroll more patients to obtain better outcomes. References: [1] Aluri, H. S., et al. (2015). Role of Matrix Metalloproteinases 2 and 9 in Lacrimal Gland Disease in Animal Models of Sjogren’s Syndrome. Investigative ophthalmology & visual science, 56(9), 5218-28. [2] Messmer, E. M., et al. (2016). Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay. Ophthalmology, 123(11), 2300–2308. https://doi.org/10.1016/j.ophtha.2016.07.028. Disclosure of Interests: None declared